Short communicationEnhanced expression of erythropoietin in the central nervous system of SOD1G93A transgenic mice
Section snippets
Acknowledgements
This work was supported by grant no. R01-2003-000-10099-0 from the Basic Research Program of the Korea Science and Engineering Foundation. This study was supported in part by year 2004 BK21 project for Medicine, Dentistry and Pharmacy.
References (28)
- et al.
Activation of the transcription factor NF-kappaB by the erythropoietin receptor: structural requirements and biological significance
Cell. Signal.
(2001) - et al.
Erythropoietin protects against brain ischemic injury by inhibition of nitric oxide formation
Eur. J. Pharmacol.
(2000) - et al.
Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils
Eur. J. Pharmacol.
(2002) - et al.
Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation
Brain Res.
(2000) - et al.
Immunohistochemical study on the distribution of insulin-like growth factor I (IGF-I) receptor in the central nervous system of SOD1G93A mutant transgenic mice
Brain Res.
(2003) - et al.
Reactive astrocytes express cAMP-response-element-binding protein (CREB) binding protein (CBP) in the central nervous system of transgenic mice expressing a human Cu/Zn superoxide dismutase mutation
Neurosci. Lett.
(2003) - et al.
Erythropoietin exerts neuroprotection in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/BL mice via increasing nitric oxide production
Neurosci. Lett.
(2001) - et al.
Cognitive impairment in amyotrophic lateral sclerosis: evidence from neuropsychological investigation and event-related potentials
Brain Res. Cogn. Brain Res.
(2002) - et al.
Visual and auditory event-related potentials in sporadic amyotrophic lateral sclerosis
Clin. Neurophysiol.
(2002) - et al.
Erythropoietin protects cultured cortical neurons, but not astroglia from hypoxia and AMPA toxicity
Neurosci. Lett.
(2000)
Recent advances in amyotrophic lateral sclerosis
Curr. Opin. Neurol.
Erythropoietin modulates intracellular calcium in a human neuroblastoma cell line
J. Physiol.
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Proc. Natl. Acad. Sci. U. S. A.
Erythropoietin and erythropoietin receptors in the peripheral nervous system: changes after nerve injury
FASEB J.
Cited by (21)
Impaired response of hypoxic sensor protein HIF-1α and its downstream proteins in the spinal motor neurons of ALS model mice
2012, Brain ResearchCitation Excerpt :In the present study, however, EPO was not increased in the anterior large MNs of Tg mice but was decreased in the surrounding glial cells. A previous study also showed that EPO expression was increased not in the anterior horn but in unaffected areas including the brainstem nuclei of ALS model mice (Chung et al., 2004). A recent study demonstrated that the EPO level in cerebrospinal fluid was lower in ALS patients than in other neurodegenerative patients (Brettschneider et al., 2006).
Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis
2007, Neuroscience LettersHigh erythropoietin and low vascular endothelial growth factor levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal response to hypoxia
2007, Neuromuscular DisordersCitation Excerpt :The behavior of the other transcription factors implicated in hypoxia (such as NF-κB, SP-1 and AP-1) should be therefore studied in ALS. Previous studies have demonstrated that EPO and its receptor (EPO-R) are expressed by tissues other than kidney and foetal liver, including the central nervous system – notably with increased immunoreactivity in the CNS of SOD1 (G93A) transgenic mice [18]. EPO in CSF may originate from three potential sources: (i) passive diffusion from the systemic circulation across a damaged blood–brain barrier (BBB), (ii) active transport across the BBB via an EPO-R-mediated system [9] and (iii) local synthesis in the CNS [19].
Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases
2006, Neuroscience LettersChallenging the validity of the EPO index
2006, American Journal of Kidney Diseases